Home / Products / Biosynthesis Chemicals / Enzyme Inhibitors / Dipeptidyl Peptidase Inhibitors /

Dipeptidyl Peptidase Inhibitors

Dipeptidyl peptidase inhibitors are a class of pharmaceutical compounds that have been developed to treat type 2 diabetes mellitus These inhibitors work by blocking the activity of the enzyme dipeptidyl peptidase-4 (DPP-4) which is responsible for breaking down incretin hormones By inhibiting DPP-4 these medications increase the levels of active incretin hormones such as glucagon-like peptide-1 (GLP-1) which in turn stimulate insulin secretion and reduce blood glucose levels In addition to their glucose-lowering effects dipeptidyl peptidase inhibitors have also been shown to promote weight loss and exhibit a low risk of hypoglycemia With their unique mechanism of action and proven efficacy dipeptidyl peptidase inhibitors have become an essential component of the treatment regimens for patients with type 2 diabetes

Get A Quote
Products Application Supporting Data Resources Related Products


Catalog Number Chemical Name CAS # Price
EI-0154 Alogliptin benzoate 850649-62-6 Online Inquiry
EI-0739 Diprotin A 90614-48-5 Online Inquiry
EI-0740 Diprotin B 90614-49-6 Online Inquiry
EI-0762 DPP IV Inhibitor, K 579 440100-64-1 Online Inquiry
EI-0763 DPP IV Inhibitor, NVP DPP 728 247016-69-9 Online Inquiry
EI-0764 DPPIV Inhibitor, P32/98 136259-20-6 Online Inquiry
EI-1347 Linagliptin 668270-12-0 Online Inquiry
EI-1469 MK-3102 1226781-44-7 Online Inquiry
EI-1956 Saxagliptin 361442-04-8 Online Inquiry
EI-2016 Sitagliptin Phosphate Monohydrate 654671-77-9 Online Inquiry
EI-2109 Talabostat mesylate 150080-09-4 Online Inquiry
EI-2143 Teneligliptin 760937-92-6 Online Inquiry
EI-2204 Trelagliptin succinate 1029877-94-8 Online Inquiry
EI-2278 Vildagliptin 274901-16-5 Online Inquiry


Dipeptidyl peptidase inhibitors or DPP-4 inhibitors have a wide range of applications in the field of medicine One key application is in the management of type 2 diabetes By inhibiting the activity of DPP-4 enzymes these inhibitors help regulate blood sugar levels by increasing the concentration of incretin hormones which stimulate insulin release and decrease the production of glucagon

Additionally DPP-4 inhibitors have shown promise in the treatment of other metabolic disorders such as obesity and non-alcoholic fatty liver disease These inhibitors have been found to improve insulin sensitivity reduce inflammation and prevent the accumulation of fat in the liver

Furthermore DPP-4 inhibitors have potential applications in the field of cancer research Studies have suggested that these inhibitors may inhibit tumor growth and metastasis by targeting the signaling pathways involved in cancer cell proliferation and migration

Overall the versatile applications of DPP-4 inhibitors make them a valuable tool in the management of diabetes and other metabolic disorders as well as a potential therapeutic option for cancer treatment

Supporting Data


Please note that all services are for research use only. Not intended for any clinical use.

Get a free quote

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.


There is no product in your cart.